A neutral, evidence-rated side-by-side of Ostarine (MK-2866, Enobosarm) and Ligandrol (LGD-4033). Figures are typical reference values, not recommendations.
| Ostarine (MK-2866, Enobosarm) | Ligandrol (LGD-4033) | |
|---|---|---|
| Type | SARM | SARM |
| Evidence level | Emerging | Emerging |
| Primary class | Non-steroidal | Non-steroidal |
| Half-life | ~24 hours | ~24-36 hours |
| Typical dose | 20–25 mg/day | 5–10 mg/day |
| Aromatises | No | No |
| Hepatotoxicity | Low | Low |
| HPTA suppression | Moderate | Moderate |
| Documented effects | 3 | 2 |
| Documented side effects | 3 | 3 |
Ostarine (enobosarm, MK-2866) is a non-steroidal selective androgen receptor modulator investigated for muscle wasting and cachexia. It is the most clinically studied SARM, having reached Phase II/III trials, yet it remains unapproved for any indication and is banned in sport. Anecdotal recreational use targets lean-mass gains at low doses, with testosterone suppression and lipid changes as the main documented downsides.
Full Ostarine (MK-2866, Enobosarm) page →Ligandrol (LGD-4033) is a non-steroidal SARM with higher potency than ostarine, studied in small Phase I trials for safety and lean-mass effects. It is popular in anecdotal recreational use for strength and size but reliably suppresses testosterone even at low milligram doses. It is unapproved, prohibited in sport, and linked to case reports of liver injury.
Full Ligandrol (LGD-4033) page →